BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 25906124)

  • 1. Small Cell Carcinomas of the Bladder Highly Express Somatostatin Receptor Type 2A: Impact on Prognosis and Treatment--A Multicenter Study of Urooncology Society, Turkey.
    Neşe N; Kumbaraci BS; Baydar DE; Kiliçaslan I; Sari AA; Şen S; Gönül II; Kankaya D; Özlük Y; Ermete M; Özağari A; Bal N; Kiremitçi S; Yildiz K; Tuna B; Şen N; Yörükoğlu K
    Appl Immunohistochem Mol Morphol; 2016 Apr; 24(4):253-60. PubMed ID: 25906124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. P53, Somatostatin receptor 2a and Chromogranin A immunostaining as prognostic markers in high grade gastroenteropancreatic neuroendocrine neoplasms.
    Nielsen K; Binderup T; Langer SW; Kjaer A; Knigge P; Grøndahl V; Melchior L; Federspiel B; Knigge U
    BMC Cancer; 2020 Jan; 20(1):27. PubMed ID: 31924180
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinicopathologic and Immunohistochemical Study of Combined Small Cell Carcinoma and Urothelial Carcinoma Molecular Subtype.
    Xiao GQ; Barrett MM; Yang Q; Unger PD
    Pathol Oncol Res; 2019 Jul; 25(3):889-895. PubMed ID: 29249035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of somatostatin and dopamine 2 receptors in neuroendocrine tumours and the potential role for new biotherapies.
    Srirajaskanthan R; Watkins J; Marelli L; Khan K; Caplin ME
    Neuroendocrinology; 2009; 89(3):308-14. PubMed ID: 19307732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Somatostatin receptor tissue distribution in lung neuroendocrine tumours: a clinicopathologic and immunohistochemical study of 218 'clinically aggressive' cases.
    Righi L; Volante M; Tavaglione V; Billè A; Daniele L; Angusti T; Inzani F; Pelosi G; Rindi G; Papotti M
    Ann Oncol; 2010 Mar; 21(3):548-555. PubMed ID: 19759190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Small cell carcinoma of the urinary bladder: a clinicopathological and immunohistochemical analysis of 81 cases.
    Wang G; Xiao L; Zhang M; Kamat AM; Siefker-Radtke A; Dinney CP; Czerniak B; Guo CC
    Hum Pathol; 2018 Sep; 79():57-65. PubMed ID: 29763719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuroendocrine Breast Carcinomas Share Prognostic Factors with Gastroenteropancreatic Neuroendocrine Tumors: A Putative Prognostic Role of Menin, p27, and SSTR-2A.
    Roininen N; Takala S; Haapasaari KM; Jukkola-Vuorinen A; Mattson J; Heikkilä P; Karihtala P
    Oncology; 2019; 96(3):147-155. PubMed ID: 30282082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inverse p16 and p63 expression in small cell carcinoma and high-grade urothelial cell carcinoma of the urinary bladder.
    Buza N; Cohen PJ; Pei Hui ; Parkash V
    Int J Surg Pathol; 2010 Apr; 18(2):94-102. PubMed ID: 20164052
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of somatostatin receptor subtype 2 and subtype 5 in thyroid malignancies.
    Woelfl S; Bogner S; Huber H; Salaheddin-Nassr S; Hatzl M; Decristoforo C; Virgolini I; Gabriel M
    Nuklearmedizin; 2014; 53(5):179-85. PubMed ID: 24967740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Somatostatin and CXCR4 chemokine receptor expression in hepatocellular and cholangiocellular carcinomas: tumor capillaries as promising targets.
    Kaemmerer D; Schindler R; Mußbach F; Dahmen U; Altendorf-Hofmann A; Dirsch O; Sänger J; Schulz S; Lupp A
    BMC Cancer; 2017 Dec; 17(1):896. PubMed ID: 29282035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicopathologic characteristics of pancreatic neuroendocrine tumors and relation of somatostatin receptor type 2A to outcomes.
    Okuwaki K; Kida M; Mikami T; Yamauchi H; Imaizumi H; Miyazawa S; Iwai T; Takezawa M; Saegusa M; Watanabe M; Koizumi W
    Cancer; 2013 Dec; 119(23):4094-102. PubMed ID: 24022344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential expression of somatostatin receptors 1-5 in neuroendocrine carcinoma of the lung.
    Tsuta K; Wistuba II; Moran CA
    Pathol Res Pract; 2012 Aug; 208(8):470-4. PubMed ID: 22770972
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of somatostatin receptor subtypes in human pituitary adenomas -- immunohistochemical studies.
    Pisarek H; Pawlikowski M; Kunert-Radek J; Radek M
    Endokrynol Pol; 2009; 60(4):240-51. PubMed ID: 19753537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Somatostatin Receptor SSTR-2a Expression Is a Stronger Predictor for Survival Than Ki-67 in Pancreatic Neuroendocrine Tumors.
    Mehta S; de Reuver PR; Gill P; Andrici J; D'Urso L; Mittal A; Pavlakis N; Clarke S; Samra JS; Gill AJ
    Medicine (Baltimore); 2015 Oct; 94(40):e1281. PubMed ID: 26447992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SSTR1 and SSTR5 subtypes are the dominant forms of somatostatin receptor in neuroendocrine tumors.
    Pisarek H; Pawlikowski M; Kunert-Radek J; Kubiak R; Winczyk K
    Folia Histochem Cytobiol; 2010 Jan; 48(1):142-7. PubMed ID: 20529830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigation of somatostatin receptor profile of neuroendocrine carcinomas of the breast.
    Kontogeorgos G; Thodou E; Choreftaki T
    Pathol Res Pract; 2020 Sep; 216(9):153066. PubMed ID: 32825939
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inverse expression of somatostatin and CXCR4 chemokine receptors in gastroenteropancreatic neuroendocrine neoplasms of different malignancy.
    Kaemmerer D; Träger T; Hoffmeister M; Sipos B; Hommann M; Sänger J; Schulz S; Lupp A
    Oncotarget; 2015 Sep; 6(29):27566-79. PubMed ID: 26259237
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of somatostatin receptor 2A immunohistochemistry, RT-qPCR, and in vivo PET/CT data in patients with pancreatic neuroendocrine neoplasm.
    Kaemmerer D; Wirtz RM; Fischer EK; Hommann M; Sänger J; Prasad V; Specht E; Baum RP; Schulz S; Lupp A
    Pancreas; 2015 May; 44(4):648-54. PubMed ID: 25872131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuroendocrine neoplasms and somatostatin receptor subtypes expression.
    Hankus J; Tomaszewska R
    Nucl Med Rev Cent East Eur; 2016; 19(2):111-7. PubMed ID: 27479788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. P53 expression in small cell carcinoma of the urinary bladder: biological and prognostic implications.
    Wang X; Jones TD; Maclennan GT; Yang XJ; Lopez-Beltran A; Eble JN; Koch MO; Lin H; Baldridge LA; Tretiakova M; Cheng L
    Anticancer Res; 2005; 25(3B):2001-4. PubMed ID: 16158936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.